文献速递鼻科

度普利尤单抗对有鼻窦手术史的慢性鼻窦炎伴鼻息肉患者的疗效

Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps.
PubMed 文献 · Int Forum Allergy Rhinol · 2021-02-21

基于SINUS-24/SINUS-52试验的事后分析,评估度普利尤单抗在慢性鼻窦炎伴鼻息肉患者中的疗效,按既往手术次数和距末次手术时间分层。724例随机患者中459例(63.4%)有至少1次既往手术。度普利尤单抗在所有亚组中均显著改善所有结局指标,且距末次手术不足3年者内镜结局改善更明显。

要点

  • 度普利尤单抗改善CRSwNP结局与手术史无关
  • 距末次手术不足3年者内镜改善更明显
  • 既往手术≥3次者基线疾病和嗅觉功能更差

核心结论

  • 度普利尤单抗改善CRSwNP结局 irrespective of surgery history,距末次手术时间较短者内镜结局改善更大。

研究设计与样本

  • SINUS-24/SINUS-52试验(NCT02912468/NCT02898454)的事后亚组分析。
  • 患者随机接受安慰剂或度普利尤单抗300 mg每2周一次。
  • 共724例随机患者,459例(63.4%)有至少1次既往手术。
  • 按既往手术次数(0、≥1、1/2、≥3次)和距末次手术时间(<3、3至<5、5至<10、≥10年)进行亚组分析。

主要发现

  • 既往手术≥3次者基线鼻息肉评分(NPS)、鼻塞(NC)、Lund-Mackay(LMK)及嗅觉功能障碍(UPSIT和嗅觉丧失)评分较无手术者更差。
  • 距末次手术<3年者基线NPS和LMK较距末次手术≥5年者更差。
  • 度普利尤单抗在所有按手术次数和距末次手术时间划分的亚组中均显著改善所有结局指标(vs 安慰剂)。
  • 距末次手术<3年者NPS和LMK改善程度大于距末次手术≥5年者。
  • 安全性结果与度普利尤单抗已知安全性特征一致。

关键数值与推荐

  • 24周疗效结局包括共同主要终点NPS和NC,以及LMK、SNOT-22和嗅觉评分。

临床怎么用

  • 对于有既往鼻窦手术史的CRSwNP患者,度普利尤单抗仍可显著改善结局,可考虑用于术后复发患者。
  • 距末次手术时间较短的患者可能从度普利尤单抗获得更大的内镜结局改善。
  • 既往手术次数较多者基线疾病更重,需关注其治疗需求。

局限性

  • 为事后亚组分析,亚组样本量未报告,统计效能可能受限。
  • 原文未报告亚组的具体效应量和置信区间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease treated with sinus surgery when refractory to medical intervention. However, recurrence postsurgery is common. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor for interleukin 4 (IL-4) and IL-13, key and central drivers of type 2 inflammation. We report the efficacy of dupilumab in patients with CRSwNP from the SINUS-24/SINUS-52 trials (NCT02912468/NCT02898454), by number of prior surgeries and time since last surgery. METHODS: Patients were randomized to placebo or dupilumab 300 mg every 2 weeks. Post hoc subgroup analyses were performed for patients with 0, ≥1, 1/2, or ≥3 prior surgeries, and for patients who had surgery within <3, 3 to <5, 5 to <10, or ≥10 years. Efficacy outcomes at 24 weeks included co-primary endpoints nasal polyp score (NPS) and nasal congestion (NC), and Lund-Mackay (LMK), 22-item Sino-Nasal Outcome Test (SNOT-22), and smell scores. RESULTS: Of 724 patients randomized, 459 (63.4%) had ≥1 prior surgery. Baseline sinus disease (NPS, NC, LMK) and olfactory dysfunction (University of Pennsylvania Smell Identification Test [UPSIT] and loss of smell) scores were worse for patients with ≥3 prior surgeries vs no surgery. Baseline NPS and LMK were worse in patients with <3 years since last surgery than in patients with ≥5 years since last surgery. Dupilumab significantly improved all outcome measures vs placebo in all subgroups by number of surgeries and by time since last surgery. Improvements in NPS and LMK were greater in patients with <3 years since last surgery than patients with ≥5 years. Safety results were consistent with the known dupilumab safety profile. CONCLUSION: Dupilumab improved CRSwNP outcomes irrespective of surgery history, with greater improvements in endoscopic outcomes in patients with shorter duration since last surgery.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Hopkins C, Wagenmann M, Bachert C, et al. Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2021. PMID: 33611847. doi:10.1002/alr.22780

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。